Przejdź do zawartości
Merck

Influence of beta-cyclodextrin and chitosan in the formulation of a colon-specific drug delivery system.

Drug research (2013-07-12)
K Rehman, M C I M Amin, S Muda
ABSTRAKT

The increase in diseases of the colon underscores the need to develop cost-effective site-directed therapies. We formulated a polysaccharide-based matrix system that could release ibuprofen under conditions simulating those in the colon by employing a wet granulation method. Tablets were prepared in a series of formulations containing a polysaccharide (beta-cyclodextrin and chitosan) matrix system along with ethylcellulose. We characterized physicochemical properties and performed an in vitro drug release assay in the absence and presence of digestive enzymes to assess the ability of the polysaccharides to function as a protective barrier against the upper gastrointestinal environment. Fourier transform infrared spectroscopy studies revealed no chemical interaction between ibuprofen and polysaccharides; however, spectrum analysis suggested the formation of an inclusion complex of beta-cyclodextrin with ibuprofen. The formulations contained 50% ethylcellulose and 50% beta-cyclodextrins (1:1) were proven to be the better formulation that slowly released the drug until 24 h (101.04 ± 0.65% maximum drug release in which 83.08 ± 0.89% drug was released in colonic medium) showed better drug release profiles than the formulations containing chitosan. We conclude that a beta-cyclodextrin drug carrier system may represent an effective approach for treatment of diseases of the colon.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Ibuprofen
Sigma-Aldrich
β-Cyclodextrin, Wacker Chemie AG, ≥98.0% (HPLC)
Sigma-Aldrich
β-Cyclodextrin, Wacker Chemie AG, ≥95.0% (HPLC)
Supelco
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-Cyclodextrin, Wacker Chemie AG
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
β-Cyclodextrin, ≥97%
Sigma-Aldrich
β-Cyclodextrin, powder, BioReagent, suitable for cell culture, ≥97%
Supelco
Ibuprofen sodium salt, ≥98% (GC)
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethyl cellulose, viscosity 100 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
Sigma-Aldrich
Ethyl cellulose, viscosity 46 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
Sigma-Aldrich
Ethyl cellulose, 48.0-49.5% (w/w) ethoxyl basis
Sigma-Aldrich
Ethyl cellulose, viscosity 4 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
Supelco
Ibuprofen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Ethyl cellulose, 48.0-49.5% (w/w) ethoxyl basis
Sigma-Aldrich
(S)-(+)-Ibuprofen, ReagentPlus®, 99%
Sigma-Aldrich
Ethyl cellulose, viscosity 300 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
Sigma-Aldrich
Ethyl cellulose, viscosity 10 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
Sigma-Aldrich
Ethyl cellulose, viscosity 22 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl